Cellular Biomedicine Group, Inc, a wholly-owned subsidiary of CBMG Holdings, develops proprietary immune cell therapies for the treatment of various cancers. We conduct immuno-oncology clinical trials using products from our integrated GMP laboratory.
Cellular cardiomyoplasty, or cell-based cardiac repair, is a new potential therapeutic modality in which progenitor cells are used to repair regions of damaged or necrotic myocardium.
The ability of transplanted progenitor cells to improve function within the failing heart has been shown in experimental animal models and in some human clinical trials.
In November 2011, a large group of collaborators at Minneapolis Heart Institute Foundation at Abbott Northwestern found no significant difference in left ventricular ejection fraction (LVEF) or other markers, between a group of patients treated with cellular cardiomyoplasty and a group of control patients.
In this study, all patients were post MI, post percutaneous coronary intervention (PCI) and that infusion of progenitor cells occurred 2–3 weeks after intervention.
In a study that is currently underway, however, more positive results were being reported: In the SCIPIO trial, patients treated with autologous cardiac stem cells post MI have been reported to be showing statistically significant increases in LVEF and reduction in infarct size over the control group at four months after implant.
Positive results at the one-year mark are even more pronounced.
Yet the SCIPIO trial was recently called into question.
Harvard University is now investigating the integrity of some of the data.
The Lancet recently published a non-specific ‘Expression of concern’ about the paper.
Subsequently, another preclinical study also raised doubts on the rationale behind using this special kind of cell, as it was found that the special cells only have a minimal ability in generating new cardiomyocytes.
Some specialists therefore now raise concerns to continue.
